NCT00581919 · FLOW

Participant flow

Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma · Source last updated 2019-12-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
id
FG000
title
Bort, Dex, and Dox With ALCAR

periods

drop Withdraws
reasons
group Id
FG000
num Subjects
8
type
Adverse Event
reasons
group Id
FG000
num Subjects
1
type
Death
reasons
group Id
FG000
num Subjects
10
type
Disease Progression
reasons
group Id
FG000
num Subjects
1
type
Physician Decision
reasons
group Id
FG000
num Subjects
1
type
Other Complicating Disease
reasons
group Id
FG000
num Subjects
2
type
Started Non-Protocol Therapy
reasons
group Id
FG000
num Subjects
1
type
Withdrawal by Subject
milestones
achievements
group Id
FG000
num Subjects
32
type
STARTED
achievements
group Id
FG000
num Subjects
8
type
COMPLETED
achievements
group Id
FG000
num Subjects
24
type
NOT COMPLETED
title
Overall Study

pre Assignment Details

No events between enrollment and group assignment. All subjects are enrolled are assigned to the same group.

recruitment Details

Participants were recruited from University of Wisconsin Hospital and Clinics and the Wisconsin Oncology Network between April 2004 and September 2010.

Complete source fields